Last quarter (Q4 2022), Pharmaxis Ltd's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Pharmaxis Ltd's net income was $―. See Pharmaxis Ltd’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Total Revenue	$ ―	$ 7.43M	$ 6.68M	$ 7.03M	$ 5.68M	$ 7.28M
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ 7.43M	$ 6.68M	$ 7.03M	$ 5.68M	$ 7.28M
Operating Expense	$ ―	$ 30.19M	$ 27.32M	$ 28.49M	$ 31.56M	$ 33.63M
Operating Income	$ ―	$ -22.77M	$ -20.64M	$ -21.47M	$ -25.88M	$ -26.35M
Net Non Operating Interest Income Expense	$ ―	$ 13.61M	$ -319.00K	$ 2.52M	$ 671.00K	$ 35.00K
Other Income Expense	$ ―	$ 7.22M	$ 17.99M	$ 5.00M	$ 5.16M	$ 32.57M
Pretax Income	$ ―	$ -1.94M	$ -2.97M	$ -13.94M	$ -20.06M	$ 6.42M
Tax Provision	$ ―	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ -8.00K
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -1.94M	$ -2.97M	$ -13.94M	$ -20.06M	$ 6.43M
Basic EPS	$ ―	$ >-0.01	$ >-0.01	$ -0.04	$ -0.05	$ ―
Diluted EPS	$ ―	$ >-0.01	$ >-0.01	$ -0.04	$ -0.05	$ ―
Basic Average Shares	$ ―	$ 562.90M	$ 407.28M	$ 394.74M	$ 381.39M	$ ―
Diluted Average Shares	$ ―	$ 562.90M	$ 407.28M	$ 394.74M	$ 381.39M	$ ―
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ -1.94M	$ -2.97M	$ -13.94M	$ -20.06M	$ 6.43M
Normalized Income	$ ―	$ -1.94M	$ -2.97M	$ -13.94M	$ -20.06M	$ 6.43M
Interest Expense	$ ―	$ -13.46M	$ 369.00K	$ ―	$ 238.00K	$ 563.00K
EBIT	$ ―	$ -15.39M	$ -2.60M	$ -21.47M	$ -19.82M	$ 6.98M
EBITDA	$ ―	$ -12.15M	$ 551.00K	$ -18.23M	$ -17.20M	$ 10.33M

Currency in USD

Pharmaxis Ltd Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing